Natera, Inc. (NASDAQ:NTRA) Shares Bought by Artemis Investment Management LLP

by · The Cerbat Gem

Artemis Investment Management LLP increased its stake in Natera, Inc. (NASDAQ:NTRA – Free Report) by 54.1% during the first quarter, HoldingsChannel.com reports. The fund owned 198,778 shares of the medical research company’s stock after buying an additional 69,751 shares during the period. Artemis Investment Management LLP’s holdings in Natera were worth $28,109,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of NTRA. LRI Investments LLC purchased a new position in shares of Natera in the fourth quarter worth approximately $29,000. Rakuten Securities Inc. lifted its position in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 119 shares in the last quarter. ORG Partners LLC acquired a new position in Natera in the 1st quarter worth approximately $32,000. Blue Trust Inc. grew its position in Natera by 223.7% during the 4th quarter. Blue Trust Inc. now owns 301 shares of the medical research company’s stock worth $48,000 after purchasing an additional 208 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Up 2.4%

NASDAQ:NTRA opened at $168.17 on Friday. The company’s 50 day moving average is $158.53 and its 200-day moving average is $158.58. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The firm has a market cap of $22.96 billion, a price-to-earnings ratio of -114.40 and a beta of 1.74.

Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analysts’ expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm’s revenue was up 36.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.56) EPS. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the subject of several research analyst reports. Morgan Stanley increased their price objective on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Robert W. Baird boosted their price objective on shares of Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a research report on Friday, February 28th. Barclays increased their target price on shares of Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, May 9th. Wall Street Zen cut shares of Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. Finally, Piper Sandler increased their price objective on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $184.63.

Check Out Our Latest Stock Report on NTRA

Insiders Place Their Bets

In other Natera news, CFO Michael Burkes Brophy sold 2,562 shares of Natera stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the sale, the chief financial officer now directly owns 75,557 shares of the company’s stock, valued at approximately $10,457,844.37. The trade was a 3.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 9,563 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $1,323,614.83. Following the completion of the sale, the chief executive officer now owns 212,541 shares in the company, valued at approximately $29,417,799.81. This represents a 4.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,755 shares of company stock worth $8,898,589 in the last ninety days. Insiders own 7.60% of the company’s stock.

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).